Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001049 | 0.94 | KDM4E (0.58) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL10001054 | 0.85 | ALDH1A1 (0.54) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL10001050 | 0.82 | KDM4E (0.70) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL9831380 | 0.81 | KDM4E (0.86) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL8106730 | 0.81 | KDM4E (0.86) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL10001052 | 0.80 | ADORA3 (0.49) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL3503405 | 0.80 | KDM4E (1.00) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL9831160 | 0.79 | KDM4E (0.64) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL14963236 | 0.79 | KDM4E (0.50) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL3775215 | 0.77 | KDM4E (0.62) | KDM4ELMNAALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492413-B2 | Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer | JSC GRINDEKS (LV) | 2013-07-23 | — | — | US | disclosed |
| US-8492413-B2 | Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer | JSC GRINDEKS (LV) | 2013-07-23 | — | — | US | disclosed |
| US-8492413-B2 | Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer | JSC GRINDEKS (LV) | 2013-07-23 | — | — | US | disclosed |
| US-20120022088-A1 | PHARMACEUTICAL COMBINATION OF 5-FLUOROURACIL AND DERIVATE OF 1,4-DIHYDROPYRIDINE AND ITS USE IN THE TREATMENT OF CANCER | JSC GRINDEKS (LV) | 2012-01-26 | — | — | US | disclosed |
| US-20120022088-A1 | PHARMACEUTICAL COMBINATION OF 5-FLUOROURACIL AND DERIVATE OF 1,4-DIHYDROPYRIDINE AND ITS USE IN THE TREATMENT OF CANCER | JSC GRINDEKS (LV) | 2012-01-26 | — | — | US | disclosed |
| US-20120022088-A1 | PHARMACEUTICAL COMBINATION OF 5-FLUOROURACIL AND DERIVATE OF 1,4-DIHYDROPYRIDINE AND ITS USE IN THE TREATMENT OF CANCER | JSC GRINDEKS (LV) | 2012-01-26 | — | — | US | disclosed |
| EP-2406218-A1 | Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer | Grindeks, A Joint Stock Company (LV) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103067-A1 | PHARMACEUTICAL COMBINATION OF 5-FLUOROURACIL AND DERIVATE OF 1,4-DIHYDROPYRIDINE AND ITS USE IN THE TREATMENT OF CANCER | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103067-A1 | PHARMACEUTICAL COMBINATION OF 5-FLUOROURACIL AND DERIVATE OF 1,4-DIHYDROPYRIDINE AND ITS USE IN THE TREATMENT OF CANCER | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2010-09-16 | — | — | WO | disclosed |
| EP-2228365-A1 | Pharmaceutical combination of 5-fluorouracil and derivative of 1,4-dihydropyridine and its use in the treatment of cancer | Grindeks, a joint stock company (LV) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022088-A1 | PHARMACEUTICAL COMBINATION OF 5-FLUOROURACIL AND DERIVATE OF 1,4-DIHYDROPYRIDINE AND ITS USE IN THE TREATMENT OF CANCER | DPYD, DHFR, FOLR1 | KDM4E 201/4885LMNA 4640/4885ALDH1A1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.